Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and OncXerna Therapeutics, Inc., a precision medicine company, announced today they have entered an...

Related Keywords

,Ashleyr Robinson ,Matt Franklin ,Stephanie Spanos ,Laura Benjamin ,Megan Jones ,Precision Oncology For Exact Sciences ,Sciences Corp ,Lifesci Partners ,Sciences On Twitter Exactsciences ,Nasdaq ,Oncxerna Therapeutics Inc ,Exchange Commission ,Science Therapy Selection Program ,Sciences Investor Contact ,Sciences Media Contact ,Sciences Forward ,European Society For Medical Oncology ,Sciences Corporation ,Exact Sciences ,Oncxerna Therapeutics ,Precision Oncology ,Exact Science ,Xerna Therapeutics ,Exact Science Therapy Selection Program ,Risk Factors ,Annual Report ,Quarterly Reports ,Xerna Investor ,Media Contact ,Plus Pembrolizumab ,Advanced Gastric ,Gastroesophageal Junction ,European Society ,Medical Oncology ,Translational Medicine ,Exact Sciences Corporation ,